5:13 PM ET
8-K
M&A Deal
Ani Pharmaceuticals Signs $676M M&A Deal with Egetis Therapeutics AB
ANI Pharmaceuticals announced a recommended public cash offer to acquire all outstanding shares, convertibles, and warrants of Sweden-based Egetis Therapeutics AB. To finance the acquisition and refinance existing debt, ANI entered into a $676 million 364-day senior bridge credit facility with JPMorgan Chase Bank. The offer price is set at SEK 11.25 per share in cash.
- Value
- $676M
- Counterparty
- Egetis Therapeutics AB (publ)